These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16287780)

  • 1. The other side of the bezafibrate infarction prevention trial data.
    McCormack J; Loewen P
    Arch Intern Med; 2005 Nov; 165(20):2431-2; author reply 2432. PubMed ID: 16287780
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C; Bulut-Streich N; Bulut D; Graf C; Mügge A; Spiecker M
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract]   [Full Text] [Related]  

  • 5. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 6. Low total cholesterol and high total mortality in patients with coronary heart disease.
    Ector H
    Eur Heart J; 1997 Aug; 18(8):1357-9. PubMed ID: 9458432
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
    Haim M; Tanne D; Goldbourt U; Doolman R; Boyko V; Brunner D; Sela BA; Behar S
    Cardiology; 2007; 107(1):52-6. PubMed ID: 16763372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease.
    Tanne D; Benderly M; Goldbourt U; Haim M; Tenenbaum A; Fisman EZ; Matas Z; Adler Y; Zimmlichman R; Behar S
    Stroke; 2006 Jul; 37(7):1720-4. PubMed ID: 16741173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.
    Younis A; Younis A; Tzur B; Peled Y; Shlomo N; Goldenberg I; Fisman EZ; Tenenbaum A; Klempfner R
    Cardiovasc Diabetol; 2016 Oct; 15(1):149. PubMed ID: 27793156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.
    Tenenbaum A; Fisman EZ; Motro M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1978; author reply 1978-9. PubMed ID: 15070976
    [No Abstract]   [Full Text] [Related]  

  • 12. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
    Haim M; Benderly M; Boyko V; Goldenberg I; Tanne D; Battler A; Goldbourt U; Behar S;
    Coron Artery Dis; 2006 Aug; 17(5):455-61. PubMed ID: 16845254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate to prevent relapsing pancreatitis in WAGR syndrome.
    Diacono D; Fagbemi A; Puleston J; Banerjee I
    BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23152176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis.
    Kurihara T; Maeda A; Shigemoto M; Yamashita K; Kamatani N
    J Gastroenterol; 2003; 38(3):300-1. PubMed ID: 12693383
    [No Abstract]   [Full Text] [Related]  

  • 16. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 17. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
    Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A;
    Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Syndrome X].
    Kotake H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():706-11. PubMed ID: 12430306
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
    Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte-suppressing effects of omega-3 fatty acids in bezafibrate-treated patients with isolated hypertriglyceridemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Eur J Intern Med; 2012 Sep; 23(6):e166-7. PubMed ID: 22863445
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.